Jodi Akin

Founder & CEO
Hawthorne Effect

Jodi is a healthcare executive, leader, innovator, advisor and serial entrepreneur. She has more than 20 years experience in clinical development, scientific and regulatory strategy, management and medtech market development from start-ups to S&P 500 companies. Prior to founding Hawthorne Effect, Inc., Jodi was Global VP Clinical Affairs at Edwards Lifesciences, LLC- where she led the seminal clinical trials and regulatory approvals for transcatheter heart valve therapy. Also a humanitarian, Jodi led international healthcare initiatives including Heart To Heart International Children's Medical Alliance, The Nahapetov Friendship Foundation and the China Heart Group, a joint venture with the United Nations Industrial Development Organization. She holds an undergraduate degree in Foreign Service from Georgetown University, Masters in Physiology and Nursing from Pace University, New York and 8 patents with a few more pending.

Rob Barmann

Partner
Endeavour Vision

Rob is a Partner at Endeavour Vision focused on medical technology investments. Rob represents Endeavour Vision on the board of Willow and he has been on the deal team for investments in IntelyCare, Nalu, Rapid Micro Biosystems and Relievant Medsystems.
Rob joined Endeavour Vision after 15 years at Boston Scientific, which has been one of the most active acquirers in medical technology in recent years. In his role as Vice President, Corporate Business Development, Rob was responsible for leading the identification, assessment and execution of Business Development transactions for Boston Scientific’s Interventional Cardiology, Peripheral Intervention and Rhythm Management divisions. This included acquisitions, divestitures, minority investments and joint ventures. Prior to his Business Development role, Rob held leadership positions in commercial strategy and marketing at Boston Scientific. Rob also previously worked at The 3M Company where he was an Engineering Project Leader. Rob holds a BS in Chemical Engineering from Northwestern University and an MBA and a Masters in Engineering Management from The Kellogg School of Management.

Christopher Brooks

Director/Healthcare Economics
Impulse Dynamics

Chris’ experience in medical devices spans 20 years, including a stint at an owner-operator of medical practices in the US and overseas. He has held sales, sales leadership and multiple healthcare economics/reimbursement roles.

Currently he serves as Director, Healthcare Economics and Reimbursement for Impulse Dynamics, a company dedicated to transforming the treatment of chronic heart failure. Chris earned degrees from Penn State University the University of Michigan.

Heather Brown

Senior Vice President, Market Access and Reimbursement
HeartFlow

Heather joined HeartFlow in 2012 to lead the software development lifecycle for the organization. With her extensive clinical and engineering background, she managed a cross-functional team implementing effective and compliant processes to deliver HeartFlow’s first FDA-cleared product in 2014. In 2016, she directed the successful re-architecture of the FFR CT product to a scalable and secure cloud-based system using Amazon Web Services infrastructure. In acknowledgement of her effective leadership, she was promoted to commercial operations to develop, launch, and manage HeartFlow’s Access Program with the mission of ensuring access to the HeartFlow Analysis for any patient who could benefit from it. Additionally, she leads the global market access and reimbursement strategy as HeartFlow gains broad coverage, in particular driving Medicare and commercial coverage in the US.

Prior to HeartFlow, Heather held senior leadership roles in several medical imaging companies. She earned a B.S. in Mechanical Engineering degree from Michigan Technological University and her M.S. and Ph.D. degrees from Vanderbilt University with a focus in neuroelectrophysiology.

David Cassak

Editor-in-Chief
MedTech Strategist

David has more than 30 years of experience in the healthcare industry. With his partner, Stephen Levin, he launched Innovation in Medtech LLC, publisher of Medtech Strategist and Market Pathways, as well as a series of international conferences. Cassak co-founded Windhover Information Inc., along with his partner, Roger Longman, in which they spun out exceptional publications such as IN VIVO, START-UP, Medtech Insight, Emerging Medical Ventures and The RPM Report. Cassak also served as Vice President, Content, and Managing Director, Medical Devices for Elsevier Business Intelligence, a Reed Elsevier Company, including the publications The Gray Sheet and The Pink Sheet. He is a frequent speaker before various companies and trade groups within the medical device industry and is widely known for his vast knowledge and reporting in MedTech.

Tak Cheung

Principal
NEA

Tak joined NEA in 2018 as a Principal on the healthcare team. He focuses on medical device investments. Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson). Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard.

Christopher Cleary

Vice President Corporate Development
Medtronic

Chris Cleary is Vice President of Corporate Development for Medtronic. During 2014, Chris led the corporate development efforts for Medtronic’s $43B acquisition of Covidien. Since then, Medtronic has acquired over 30 businesses for more than $3 billion, and made more than 20 investments in companies and funds in excess of $170 million. Prior to 2014, Chris was CEO of Alesia Capital Services, and worked at GE Capital from 1995 to 2011, leading M&A teams that closed acquisitions worth $60 billion of financial assets across more than 200 transactions.

Andrew Cleeland

CEO
Fogarty Innovation

Andrew is a seasoned executive with over 30 years’ experience in the medical device industry. During this time, he has held key leadership positions in organizations ranging from early stage start-ups to large multinationals. In joining Fogarty Innovation he further broadens this range of experience to include managing a non-profit. The versatility required to be effective across such diverse groups is rare and is a testament to Andrew’s strong leadership skills. Andrew has received numerous awards and honors and is a frequent invited lecturer at major industry conferences and leading academic institutions.

Paul Conover

Partner
Knobbe Martens

Paul N. Conover is a partner in Knobbe Martens’ Orange County, CA office. He leads teams of attorneys in strategically obtaining patents domestically and internationally, performing due diligence in transactions involving intellectual property, developing and implementing licensing strategies, performing market clearance and engineering design-around efforts, and enforcing patents and defending against patents in the pre-litigation stages. Mr. Conover works with clients in multiple areas of technology, including many types of medical devices, optics, and consumer products. He has spoken at many events on intellectual property topics, including in Brazil, India, and the United States. He has also published on many intellectual property topics, including regarding the recent decisions by the U.S. Supreme Court on patent law.

Ingrid Ellerbe

Executive Director of Diversity by Doing (DxD)
Stanford Biodesign

Ingrid is the executive director of Diversity by Doing (DxD), a healthtech initiative developed by Stanford Biodesign and Fogarty Innovation. At DxD her mission is to lead the endeavor of being a transformational force for diversity through an industry-wide initiative formed to raise awareness of inequity, help individuals take action to create a more just and inclusive environment, and provide programs and resources that support systemic change. These efforts span the pipeline from students interested in health technology to start-up and mid-sized healthtech company operations and the myriad of entities that are included in the ecosystem. She has spent the past 30 years working to help underserved communities succeed in the technology and education industries. Previously, she served as the Executive Director of Base 11, a nonprofit workforce and entrepreneur development company that helps women and minorities succeed in STEM. During her tenure, Ingrid grew participation from three community colleges to 15, developed partnerships with universities, institutions and corporate sponsors across the country, and built programs to provide advanced technology training. Prior to that, she held leadership roles at several innovative educational technology companies, in both the private and nonprofit sectors. The two things that Ingrid finds most motivating are driving people to STEM careers and seeing the positive impact of those choices. She is a trustee of the NAACP Foundation, and serves on the boards of Project Tomorrow, Hines Family Foundation and Better Days Integrated Programs (Bdips). She holds a BA in communications from California State University Dominguez Hills.

David Filmore

Executive Editor
Market Pathways

David has been covering the medical technology sector as a writer and editor for about 20 years, previously serving as the executive editor/editor-in-chief of industry-leading publications The Gray Sheet and Medtech Insight. He specializes in the regulatory and reimbursement dynamics that impact device and diagnostics companies' ability to succeed in the marketplace. Earlier in his career, David was an editor with the American Chemical Society, producing content for professionals in the pharmaceutical industry and analytical instrumentation space, and he has also worked in the pharmaceutical industry.

Kate Garrett

Managing Partner
Sonder Capital

Kate Garrett has experience in the medical device industry as a serial inventor, entrepreneur and operator across the spectrum of early stage start-up to large multi-national organizations.

Prior to Sonder Capital, Kate co-founded Ciel Medical, a critical care company, where as CEO she led a team in the invention, development and commercialization of three products for ventilated patients. Ciel was acquired by Vyaire Medical in 2017 and Kate transitioned to Vice President of Airway Technologies at Vyaire.

She has co-authored over a dozen patents including technologies in urology, critical care, women’s health and vascular surgery. She currently serves as chairman of the board of directors for Brius, an orthodontia company, and is the Assistant Director of the Stanford Biodesign Innovation Fellowship.

Hanson Gifford, III

Partner
Lightstone Ventures

Hanson is a Partner of LSV. He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. He has served in this role since November 2013. Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV. Since its inception in 1998, Hanson has led The Foundry in all of its activities. Prior to The Foundry, Hanson was Vice President of Research and Development at Heartport, Inc., which had a successful IPO in 1996. From 1993-1998, he built and led a 62-person team at Heartport developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. In 1992-1993, Hanson co-founded and served as Managing Director of Bavaria Medizin Technologie, GmbH in Oberpfaffenhofen, Germany. In 1991, Hanson co-founded and served as President of Cardiovascular Therapeutic Technologies (acquired by Eli Lilly). From 1985-1990, Hanson worked at Devices for Vascular Intervention (acquired by Eli Lilly) in various engineering, clinical research and marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics. Hanson is a named inventor on over 360 issued US patents. Hanson is a Director of FIRE1, Contego, Reprieve Cardiovascular, Half Moon Medical, Tangible Science, and Foundry Therapeutics 2.

Daniel Hawkins

CEO
Avail Medsystems

Daniel Hawkins is the founder and CEO of Avail Medsystems, a medical technology company creating a network where medical expertise sharing can occur between healthcare professionals and experts to and from the operating room anytime, anywhere. Over the past 25 years in the medical technology field, Daniel’s mission has been to identify and close gaps that prevent patients from getting the best possible healthcare. He is an inventor on over 140 patents and applications, and has held roles in both large and emerging companies, including Advanced Cardiovascular Systems, Inc., Endologix, Restore Medical, EnteroMedics, and Intuitive Surgical. Daniel is a co-founder of Calibra Medical, acquired by Johnson & Johnson, and founder of Shockwave Medical, Inc. (NASDAQ: SWAV). Daniel has an MBA from Stanford University and a BS in Economics from The Wharton School of the University of Pennsylvania. In 2017, Daniel was honored by Goldman Sachs as one of its Top 100 Most Intriguing Entrepreneurs.

Steven Hochberg

Partner
Deerfield Management

As a Partner on the Private Transactions team at Deerfield, Steve joined Deerfield in 2013 to work on structured transactions in Deerfield’s Private Design Funds. Steve has been a founder and manager of healthcare companies for more than 20 years. Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies. Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is the Senior Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $5 Billion in annual revenues. He graduated from the University of Michigan and earned his M.B.A. from Harvard Business School.

Curtis Huffmire

Partner
Knobbe Martens

Curtis R. Huffmire is a partner in Knobbe Martens’ Orange County, CA office. His practice focuses on patent litigation, prosecution, counseling and licensing. He has experience in mechanical, medical, and electronic devices, systems and methods. Mr. Huffmire represents clients in a wide range of technologies, including medical devices and procedures, vehicle systems, surveillance systems, electro-mechanical systems, and materials engineering. Mr. Huffmire is a member of the litigation team representing clients in the enforcement of their intellectual property rights and responding to the allegations of their competitors. Mr. Huffmire also works with clients to obtain patent protection on their new products and ideas. His practice includes counseling clients regarding patent infringement, patent validity, licensing, and right-to-practice issues.

Ankur Kaushal

Vice President, Quality & Regulatory Affairs
Big Health

Ankur Kaushal serves as the Vice President, Quality & Regulatory Affairs at Big Health, leading the Quality and Regulatory compliance activities for digital therapeutics to address mental health disorders. In this role, Ankur is focused on advancing compliance best practices to effectively realize the unique opportunities and benefits offered by software development techniques and lifecycles.

Prior to joining Big Health, Ankur led regulatory affairs activities for next generation sequencing based oncology diagnostics at Roche. Ankur has also previously served in regulatory affairs and quality systems roles at Abbott Laboratories, Medtronic and Johnson & Johnson. Ankur received his Master’s degree in Biomedical Engineering from the University of Southern California, Los Angeles.

Daniel Kraft

Faculty Chair of Medicine
Singularity University

Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur, and innovator and is serving as the Chair of the XPRIZE Pandemic Alliance Task Force. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has chaired the Medicine for Singularity University since its inception in 2008, and is founder and chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children’s Hospital, and fellowships in hematology, oncology and bone marrow transplantation at Stanford.

Irfan Lateef

Partner
Knobbe Martens

Irfan Lateef is head of the firm’s Electrical, Semiconductor & Computer Technology Litigation committee and also leads the firm’s Japan practice. With over two decades of experience, Irfan ranks among the premier IP litigators in the "World's Leading Patent Professionals" for the Patent 1000 guide by Intellectual Asset Management (IAM) magazine.  Clients turn to Irfan to tackle some of their most technically complex issues. His engineering background gives him the ability to master the technology.  His experience includes advanced signal processing and digital and analog circuitry.  With a master’s degree in Biomedical Engineering, he possesses unique insight for medical device litigation.  He is familiar with noninvasive patient monitoring, breath analyte monitoring, blood component separation, atrial fibrillation devices, ECG and EEG signal processing, imaging (e.g., MRI), and acoustic signal processing. 

Howard Levin

CEO
Deerfield Catalyst

Founder
Coridea

A veteran in the field of biomedical engineering and cardiology, with a specialty in heart failure and transplantation, Dr. Levin brings more than 35 years of clinical and commercial healthcare experience to his role. In 2003, with Mark Gelfand, Dr. Levin co-founded Coridea. His inventions and co-inventions have successfully launched or their patents helped launch companies including Ardian (Medtronic), CHF Solutions (Gambro), Respicardia (formerly, Cardiac Concepts), eValve (Abbott) and RenalGuard/Reprieve Cardiovascular (PLC Medical), Cibiem and Soffio Medical. He has held a number of positions in these companies including President, Chief Scientific Officer, Chief Medical Officer and VP of R&D. Dr. Levin received his M.D. from the Mt. Sinai School of Medicine and his training in cardiology at The Johns Hopkins School of Medicine. He also has a master’s degree in Biomedical Engineering.

Stephen Levin

Editor-in-Chief
Market Pathways

Stephen Levin has spent nearly 25 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide. Before Levin and his partner, David Cassak, launched Innovation In Medtech, LLC, the parent company of MEDTECH STRATEGIST and MARKET PATHWAYS, along with international conferences, Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI). At EBI, he directed the editorial coverage for the company’s leading medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences. He is a frequent speaker at medical device conferences and for companies worldwide on a variety of topics related to the medtech industry

Tracy MacNeal

CEO
Materna Medical

Tracy MacNeal leads the Materna team, bringing over 20 years of expertise in MedTech and women’s health to Materna’s exciting technology platform. She holds a BE in Chemical Engineering from Cooper Union and an MBA from Duke University.

Josh Makower

Director & Co-founder
Stanford Biodesign

Dr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.

Dennis McWilliams

Partner
Santé

Dennis is a serial life science entrepreneur and innovator dedicated to globally commercializing medical technologies.

Prior to joining Santé, Dennis founded SparkMed Advisors, a boutique advisory to the medical device space, Apollo Endosurgery, a medical device company developing novel flexible surgical devices for less invasive surgery, and co-founded Chrysalis BioTechnology‚ a development-stage biopharmaceutical company focused on novel drug therapies for tissue regeneration. He started his career as an analyst for the IC2 Institute, a global think tank focused on applied entrepreneurship and commercialization research.

Dennis also serves as Co-Course Director for the B.E.S.T. Innovation Course, taught at the IHU Institute in Strasbourg France, is a member of the Center for BioDesign’s Advisory Counsel at Johns Hopkins University and is a frequent lecturer in the Stanford BioDesign Fellowship program.

Dennis earned his MS in engineering management from Stanford University and his BS in aerospace engineering, with honors, from the University of Texas.  He has served on the Board of Directors for the Texas Exes and University of Texas Men’s Athletic Counsel, been named a Distinguished Engineering Graduate and an Outstanding Young Texas Ex and is a member of the Academy of Distinguished Alumni for the Department of Aerospace.

Jonathan Norris

Senior Managing Director, Healthcare Practice
Silicon Valley Bank

Jonathan Norris is a managing director for business development in SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations. In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than nineteen years of banking experience working with healthcare companies and venture capital firms. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

Marga Ortigas-Wedekind

Chief Commercial Strategy Officer
Fogarty Innovation

Marga is a seasoned executive with 30+ years of experience in medical technology and digital health companies. She is a team player having led multiple functions and departments, with international and domestic market involvement. She is a board member at three medical technology companies at various stages of maturity. Marga has served in advisory functions for small companies through her role at Fogarty Innovation and as an advisory board member at Launchpad Digital Health (LDH).  Marga was born and raised in the Philippines, speaks fluent Spanish and Tagalog and is thrilled to join the BACC community, hoping to use her language and medical technology skills to reach out to patients in the community in whichever way fills the biggest need.

Yarmela Pavlovic

Vice President of Regulatory Strategy
Medtronic

** Bio coming soon!

Adi Renbaum

President
ANR Consulting

Adi Renbaum, President of ANR Consulting, is a seasoned and trusted business advisor to executives of advanced medical technology companies, specializing in health policy, medical economics, and reimbursement strategies. For more than 22 years, Ms. Renbaum has designed and implemented market access strategies for advanced medical therapeutics and diagnostics using a consultative problem-solving approach. Applying her keen understanding of healthcare financing dynamics, she leverages and influences health policies to create access to novel technologies in existing treatment pathways. She helps her clients highlight their technologies’ clinical merits and impact on patients’ functional improvements, and the economic benefits that follow integrating a new technology into the treatment pathway – keys to products’ value propositions for stakeholder adoption, diffusion and payment.

Duke Rohlen

CEO
Ajax Health

Duke serves as CEO and Managing Director of Ajax Health. He also serves on the board of current Ajax companies Ablacon (Executive Chairman), Serpex Medical (Executive Chairman), Verix Health (Executive Chairman) and Foresight. He has over 20 years of experience as an executive in medical device companies. Prior to Ajax, Duke co-founded and served as the Chairman and CEO of EPIX Therapeutics, which was acquired by Medtronic in 2019. Prior to EPIX, Duke served as co-founder and CEO of Spirox, which was acquired by Entellus in 2017. Prior to Spirox, he co-founded and served as CEO of CV Ingenuity, which was acquired by Covidien in 2013. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies before being named President. In this role, Duke led the sale of the company to ev3 (now Medtronic) in 2008. Prior to FoxHollow, Duke served as an entrepreneur-in-residence at the private equity firm Alta Partners. Duke began his professional career as the co-founder and President of a 9-unit, ~$20 million per year restaurant company. Duke currently serves as a Trustee of the United States Ski and Snowboard Association. Duke received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

Nicole Walker

Managing Partner
Arboretum Ventures

Nicole joined Arboretum Ventures in 2021 as a Managing Partner, where she focuses on early-to-growth stage healthcare investments. Current areas of interest include pharma-adjacent tools & analytics; devices; and tech-enabled solutions which transform healthcare delivery by improving the overall access, cost, and quality of care for unmet therapeutic needs. For more than 25 years, Nicole has successfully partnered with entrepreneurs to modernize and transform the healthcare industry. She strongly believes in the power of teams and in the importance of bringing diversity across all levels when building effective organizations. Her notable investments and board roles prior to joining Arboretum include category-defining companies such as Cala Health, Elucent Medical, MI Biosciences (acquired), NeoChord, NeuMoDx Molecular (acquired), and Strata Oncology. Nicole joins Arboretum Ventures from Baird Capital, where she was a managing director and partner, having co-led the team’s healthcare investments since 2013. Prior to Baird, Nicole was an investment director at Abbott Ventures and Abbott Biotech Ventures, helping to stand up the original investment organization for the corporation. Nicole began her career as a process engineer with Advanced Cardiovascular Systems/Guidant, where she spent ten years advancing through increasing roles of responsibility in product development, marketing, and strategy.

Andrew Weiss

President & CEO
ReCor Medical

Mr. Weiss brings over 20 years experience in the Medical Device Industry, starting with global management responsibilities at GE Medical Systems. Mr. Weiss left GE to become Vice President of Sales & Marketing at Marquette Medical Systems. Following Marquette, Mr. Weiss became President & CEO of Vital Images, a company he took public in 1996. Mr. Weiss then joined Medtronic as VP & General Manager of its Surgical Navigation Systems business, following which he became VP & General Manager of the Medtronic Neurological business. Prior to joining ReCor Medical, Mr. Weiss served as President & CEO of CoAxia, Inc. Mr. Weiss is a graduate of the Massachusetts Institute of Technology with a degree in mechanical and electrical engineering and has an MBA from the Columbia University Graduate School of Business.